AS703206 is a novel, selective, and orally bioactive MEK1/2 inhibitor that has potent cytotoxicity on tumor cells for the majority of patients with relapsed and refractory multiple myeloma (73). This evidence concerns the gene MAP2K1 and AL amyloidosis.